Press

Field Trip Health & Wellness to Close Clinics in 5 Locations

Mar 15 • 2 min read

Field Trip Health & Wellness Ltd. (TSX-V: FTHW) today announced that, in an effort to reduce expenditures and preserve capital, it will be closing the Field Trip Health Centres located in Chicago, Washington DC, Seattle, San Diego and Fredericton. The anticipated last day of operation for each of these locations will be on or around…

Filament Health Announces FDA Approval of Phase II Clinical Trial Studying Psilocybin for Methamphetamine Use Disorder

Mar 15 • 2 min read

Filament Health Corp. (OTCQB: FLHLF / NEO: FH / FSE: 7QS), a clinical–stage natural psychedelic drug development company, today announced approval from the United States Food and Drug Administration (FDA) for a clinical trial at the University of California San Francisco’s Translational Psychedelic Research Program (TrPR). The investigator initiated trial will study the effects of PEX010, Filament’s botanical…

BetterLife Closes $1,857,143 of Private Placement

Mar 15 • 3 min read

BetterLife Pharma Inc. (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce the closing of its brokered private placement offering pursuant to which the Company issued 15,000,000 units of the Company (“Units”) at a price of $0.10 per Unit for aggregate gross…

Clearmind Medicine Appoints Professor Henry R. Kranzler, M.D., to Scientific Advisory Board

Mar 15 • 3 min read

Clearmind Medicine Inc. (Nasdaq: CMND / CSE: CMND / FSE: CWY), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the appointment of Professor Henry R. Kranzler, M.D., as the newest member of its Scientific Advisory Board (“SAB”). Professor Kranzler is the Benjamin Rush…

Mindset Pharma To Defend Against Lawsuit Filed By Reunion Neurosciences

Mar 15 • 2 min read

Mindset Pharma Inc. (CSE: MSE / FSE: 9DF / OTCQB: MSSTF), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced that the Company has been made aware that Reunion Neuroscience Inc. (“Reunion”) has filed a lawsuit against Mindset in the United…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435